Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Return on Sales (2018 - 2026)

Sunshine Biopharma filings provide 10 years of Return on Sales readings, the most recent being 0.01% for Q4 2025.

  • On a quarterly basis, Return on Sales changed 0.0% to 0.01% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.0%, a 0.0% change, with the full-year FY2025 number at 0.0%, changed 0.0% from a year prior.
  • Return on Sales hit 0.01% in Q4 2025 for Sunshine Biopharma, up from 0.0% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.08% in Q4 2021 to a low of 1.54% in Q1 2021.
  • Median Return on Sales over the past 5 years was 0.0% (2023), compared with a mean of 0.16%.
  • Biggest five-year swings in Return on Sales: plummeted -136bps in 2021 and later surged 144bps in 2022.
  • Sunshine Biopharma's Return on Sales stood at 0.08% in 2021, then tumbled by -176bps to 0.06% in 2022, then skyrocketed by 97bps to 0.0% in 2023, then soared by 377bps to 0.0% in 2024, then surged by 31bps to 0.01% in 2025.
  • The last three reported values for Return on Sales were 0.01% (Q4 2025), 0.0% (Q3 2025), and 0.0% (Q2 2025) per Business Quant data.